申请人:AstraZeneca AB
公开号:US20170152254A1
公开(公告)日:2017-06-01
A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, where: Q can be 5-methylpyridazin-3-yl, 5-chloropyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R can be hydrogen, fluoro, or methoxy; R
1
can be hydrogen, methoxy, difluoromethoxy, or trifluoromethoxy; and R
2
can be methyl or ethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
化合物式(I)的复合物:或其药学上可接受的盐,其中:Q可以是5-甲基吡嗪-3-基,5-氯吡嗪-3-基,6-甲基吡嗪-3-基或6-氟吡嗪-3-基;R可以是氢,氟或甲氧基;R1可以是氢,甲氧基,二氟甲氧基或三氟甲氧基;R2可以是甲基或乙基。化合物式(I)的复合物可以抑制谷氨酰胺酶,例如GLS1。